Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up After Earnings Beat

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s stock price gapped up before the market opened on Friday following a stronger than expected earnings report. The stock had previously closed at $16.47, but opened at $17.82. Adaptive Biotechnologies shares last traded at $16.1370, with a volume of 116,138 shares.

The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 48.73%. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The firm’s revenue was up 51.0% on a year-over-year basis.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research report on Friday. Guggenheim increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday. Finally, BTIG Research boosted their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average price target of $17.56.

Insiders Place Their Bets

In other news, insider Francis Lo sold 113,890 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30. Following the transaction, the insider directly owned 315,978 shares of the company’s stock, valued at approximately $4,919,777.46. This trade represents a 26.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sharon Benzeno sold 308,477 shares of Adaptive Biotechnologies stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $16.91, for a total transaction of $5,216,346.07. Following the sale, the insider owned 296,791 shares in the company, valued at approximately $5,018,735.81. This represents a 50.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 1,612,461 shares of company stock worth $27,754,413. 6.40% of the stock is owned by company insiders.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently made changes to their positions in ADPT. Brighton Jones LLC increased its stake in shares of Adaptive Biotechnologies by 3.1% during the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC lifted its position in Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock worth $641,000 after purchasing an additional 904 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Adaptive Biotechnologies by 3.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock valued at $355,000 after purchasing an additional 910 shares in the last quarter. California State Teachers Retirement System boosted its stake in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after purchasing an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors increased its position in shares of Adaptive Biotechnologies by 7.6% during the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Performance

The company has a market cap of $2.41 billion, a P/E ratio of -39.42 and a beta of 2.18. The stock has a 50 day moving average price of $17.03 and a 200 day moving average price of $15.20.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.